The following are excerpts from the Boston Globe Trendlines article published on July 13, 2026 by Robert Weisman and titled: “Anthropic’s Claude Science app is coming for Kendall Square.”
Few places on the planet have more at stake in AI’s transformation and disruption of life sciences than the Massachusetts biomedical ecosystem centered in Kendall Square and Boston’s sprawling hospital research sites.
The Bay State accounts for nearly a sixth of the total US drug development pipeline and drew more than 20 percent of the nation’s venture funding for biotech startups last year, according to a report from the industry group MassBio. Its roughly 50 million square feet of lab space is the largest of any US market, according to commercial real estate firm JLL.
But the state has seen a sharp drop in private investments and the National Institutes of Health grants that bankroll academic research labs as the Trump administration cut research funding over the last two years. And the vacancy rate for the state’s biomedical labs is roughly 30 percent, higher than rival clusters in San Francisco and San Diego.
Against that backdrop, AI has the potential to exponentially boost the process of matching drug compounds with cell mutations.That could lead to more drugs targeting hard-to-treat illnesses, along with higher sales and profits for drug makers. But there are fears it could also hasten a trend, already underway, of paring down jobs in research labs.
Some see AI reshaping, rather than hollowing out, biotech employment, fueling demand for new skills and rewarding employees who analyze as well as generate data on drug compounds and test results. Whether the new mix will also mean employment at today’s levels remains to be seen.
AI is also creating a cohort of new “tech-bio” companies that combine AI apps and data analytics with traditional drug discovery methods. MassBio runs an accelerator program called DRIVE that pairs tech-bio entrepreneurs with seasoned biotech executives to share resources and “upskill” workers in AI.
“We want these tech-bio companies to know they have a home here in Massachusetts,” said Jason Cordeiro, MassBio’s chief operating and innovation officer.
